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Case Report
Intrathecal baclofen as emergency treatment
alleviates severe intractable autonomic
dysreflexia in cervical spinal cord injury
Elmar M. Delhaas, Sander P.G. Frankema, Frank J.P.M. Huygen
Center for Pain Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Context: Episodic attacks of autonomic dysreflexia (AD) are regularly experienced by patients with a spinal cord
injury (SCI) on T6 or higher levels. The episodes can result in a pounding headache, flushing, blurred vision,
anxiety, a stroke, posturing, hyperthermia, retinal bleeding, seizures, myocardial ischemia, cardiac
arrhythmias, and death. The observed associated bradycardia is explained as a baroreceptor reflex
response to the high blood pressure. Intrathecal baclofen (ITB) has been used to treat chronic AD. This case
highlights the occurrence of intractable AD after removal of the ITB delivery system because of a pump
pocket infection. We describe the benefit of ITB as an emergency treatment for intractable AD.
Findings: A 53-year-old male suffered from spasticity and AD after a C5 ASI B SCI in 2002 was successfully
treated with ITB for 14 years. He developed Staphylococcus aureus and Pseudomonas aeruginosa cellulitis
at the orifice of his suprapubic catheter, which caused an abscess in the pump pocket. To prevent a
withdrawal syndrome, the medication was reduced in three steps of 25%, and the pump was explanted.
Postoperatively, he experienced severe AD and was treated with clonazepam, clonidine, and urapidil. The
next day, the severely fluctuating blood pressure and pulse rate were no longer controllable with the
medication. At L2-3, a temporary external intrathecal catheter for reinitiating ITB was inserted. With this
treatment, the AD and the spasticity symptoms could be controlled.
Conclusion/Clinical Relevance: The case demonstrated that refractory AD could be managed with ITB in an
emergency.
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Introduction
Episodic attacks of autonomic dysreflexia (AD) (“sym-
pathetic storm”) are regularly experienced by patients
with a spinal cord injury (SCI) on T6 or higher levels
(above the outflow to the splanchnic and renal vascular
beds).1–5 Noxious or innocuous visceral or somatic
stimuli below the SCI lesion such as bladder and
bowel irritation1,3,6 can lead to a sudden excessive sym-
pathetic response. Spasticity, pain, sexual activity, preg-
nancy, delivery, pressure sores, and iatrogenic medical
procedures are also known to trigger AD.1,3,7 Loss of
descending inhibition results in higher levels of
norepinephrine release, which is responsible for cold,
pale skin vasoconstriction below the level of injury.3,8
The observed associated bradycardia is explained as a
baroreceptor reflex response to the high blood
pressure.2,3,6 The AD syndrome varies from silent,
mild forms with diaphoresis above the lesion and piloer-
ection to a severe, life-threatening situation.2,7 These
attacks can happen up to 40 times a day.4 The episodes
can result in a pounding headache, flushing, blurred
vision, anxiety, a stroke, posturing, hyperthermia,
retinal bleeding, seizures, myocardial ischemia, cardiac
arrhythmias, and death.1–3 Intrathecal baclofen (ITB)
has been used to treat chronic AD.9,10 We report the
application of ITB in an emergency case of acute
intractable sympathetic storm. After the approval of
the medical ethics committee of Erasmus Medical
Correspondence to: Elmar M. Delhaas, Center for Pain Medicine, Erasmus
MC University Medical Center, Rotterdam, The Netherlands. E-mail: e.
delhaas@erasmusmc.nl
Color versions of one or more of the figures in the article can be found online
at www.tandfonline.com/yscm.
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/
licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not
altered, transformed, or built upon in any way.
DOI 10.1080/10790268.2019.1695080 The Journal of Spinal Cord Medicine 2019 1
Center (MEC-2017-326), we retrospectively studied the
case. The requirement to obtain informed consent was
waived.
Presentation of the case
A 53-year-old male suffered from spasticity and AD
after a C5 ASI B SCI in 2002. Initially this complaint
was controlled with oral baclofen. Due to progression
of spasticity, ITB was administered after two years.
For fourteen years, the patient was treated with ITB
using an implanted infusion system (SynchroMed II,
Medtronic Inc., Minneapolis, MN, USA). During that
time, a neuropathic pain developed below the level of
the SCI and morphine was added to the ITB.
Complaints were again under control with intrathecal
morphine of 1.2 mg/day and ITB of 192 mcg/day.
More recently, the patient developed a cellulitis at the
orifice of his suprapubic catheter. Initially, we started
with flucloxacillin 4 g/day. After the bacteriological
culture revealed both Staphylococcus aureus and a
Pseudomonas aeruginosa, the antibiotic treatment was
changed to piperacillin/tazobactam 16/2 g/day, and
vancomycin 2g/day. The local infection quickly subsided
with the antibiotic treatment, but the development of
erythema and swelling around the pump in the left
abdominal wall indicated that the infection had spread
to the device. We feared that the abscess would force
the infection to spread along the catheter to the epidural
and intrathecal space in a matter of days.
Explantation of the pump was thus deemed necessary.
To prevent a withdrawal syndrome, we reduced the
medication in three steps by 25%. Concomitantly, as a
cross titration we started with oral baclofen and trans-
dermal fentanyl (50 mcg). As intrathecal baclofen was
still administered, we started with a low oral baclofen
dose of 40 mg, which was increased to 80 mg while con-
comitantly reducing the intrathecal administration. At
day four we removed the entire device. We did not
find any sign of an infection dorsally at the catheter
insertion site, but we identified an abscess in the
abdominal pump pocket. The day thereafter, the
patient developed episodic a severe headache, excess
perspiration and piloerection in the upper part of the
body, and severely varying blood pressures (BP), and
pulse rates (PR), without pain, fever, respiratory insuffi-
ciency, and with except for a C-reactive protein of 73
mg/ml and an alkaline phosphatase of 135 U/l all lab-
oratory values were normal and remained unchanged in
the following days (Fig. 1). Thereby was his spasticity
under control with oral baclofen and intravenous clona-
zepam. With a diagnosis of AD, related with a withdra-
wal syndrome, the patient was admitted to the ICU and
initially was successfully treated with a mixture of clona-
zepam, clonidine and urapidil. However, the next day
the clinical situation was complicated by the patient’s
diminished consciousness, later diagnosed as a posterior
reversible encephalopathy syndrome (PRES).11 The
severely fluctuating BP and PR returned, and the
maximum tolerable oral and intravenous substitution
was insufficient to compensate for the prior highly effi-
cient route of administration of his baclofen.
A distinct subarachnoid hemorrhage (SAH) in the left
frontal lobe was identified with MRI (Fig. 2). To allevi-
ate the AD, we inserted at L2-3 a temporary external
catheter (Perifix 19G, B. Braun, Oss, The Netherlands)
30 cm intrathecal for reinitiating ITB. After a positive
50 mcg single bolus, we titrated ITB up to 240 mcg/
day using a standard syringe pump. With this treatment,
we could manage the AD and the spasticity symptoms.
After one week, we removed the temporarily external
catheter and replaced it with a definite intrathecal
Ascenda catheter (Medtronic Inc., Minneapolis, MN,
USA). In order to bridge the time until the pump
pocket infection was cured, we temporarily connected
the catheter to a subcutaneously implanted portal
system (Porthales 4000, Tricumed Medizintechnik
GmbH, Kiel, Germany) at the opposite site (costal
10–11 level). After a dose titration ITB up to 384
mcg/day using a CADD-Solis external pump (Smiths
Medical ASD, Inc., St. Paul, MN, USA), we discharged
the patient from the hospital. Ten weeks later, we
removed the portal system and connected the catheter
Figure 1 Autonomic Dysreflexia: Severe fluctuations in blood pressure (black arrow) and pulse rate (gray arrow).
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to a new pump in the lower right abdominal quadrant.
The patient gradually recovered from the PRES. His
spasticity and AD were brought under control with
ITB of 384 mcg/day, and his pain by intrathecal mor-
phine of 1.2 mg/day.
Discussion
To our review, emergency resumption of ITB as treat-
ment of life-threatening withdrawal syndrome with
AD that has not been reported before. The cyclic char-
acter, the excessive regional perspiration, piloerection in
the absence of pain and missing symptom control by an
additional administrated opioid, we assumed opioid
withdrawal was not likely. To preempt or minimize a
withdrawal syndrome,12 we performed a cross titration
initially with only oral baclofen, and later with the
addition of clonazepam; furthermore, to prevent an
opioid withdrawal, we used transdermal fentanyl. In
our practice, we wean the intrathecal medication arbitra-
rily in steps of 25% while concomitantly starting oral
and transdermal treatment. This manner of weaning is
the compromise to prevent a withdrawal syndrome
versus the potential for development of meningitis.
Based on our experience, we assume the same clinical
aggravation would have emerged after a slower
weaning protocol. Thereby, it should be taken into con-
sideration that the fear the abscess would force the infec-
tion to spread along the catheter to the epidural and
intrathecal space in a matter of days is the reason for
other physicians deciding upon the immediate removal
of the implanted infusion system, thus preferring to
take the risk of a withdrawal syndrome instead of the
development of severe meningitis. The symptomatology,
in this case, differed from the regular ITB withdrawal
syndrome, as his spasticity was under control with no
signs without fever, respiratory insufficiency, or a multi-
organ failure. Our patient was previously diagnosed
with severe AD that was successfully suppressed with
ITB. The patient exhibited intractable sympathetic
storms as a result of a spasticity exacerbation. Possible
confounding factors could be the cessation of intrathe-
cal morphine and the presence of an infection, which
itself could lead to an autonomic disturbance.
However, AD did not occur in the previous cellulitis
at the orifice of the suprapubic catheter period, but
developed several days later. Per protocol, we explored
the common causes of an autonomic disturbance,
including bowel, bladder, and skin problems. Also, a
physical examination and computed tomography did
not reveal additional treatable disorders to remove
the triggers. Also, to our best knowledge a relation
between the presence of morphine in the ITB pump
and the development of AD is unknown. A primary
concern is the paucity of knowledge of the syndrome
AD among caregivers8 and additionally the limited
knowledge of ITB, in particular its value in preventing
AD.9,10 We observed a protracted duration of the syn-
drome over hours, which is consistent with prior
studies.13,14 The patient revealed an excessive fluctuat-
ing BP and PR. the patient’s varying systolic BP of 90
to 155 mmHg exceeds the norm of 150 mmHg5,7 as well
as the sudden 20–40 mmHg elevation7,15 and should
therefore also be considered excessive. Moreover, the
associated HR of 149/min was extreme. Because we
could not control the clinical situation with the
applied medication, we were forced to reinitiate ITB.
With no sign of a local dorsal infection, clear CSF,
and a CSF Gram examination that had not revealed
microorganisms at the removal of the implanted
device, we decided upon a catheter insertion, although
we were at that time not informed about the bacterial
culture. We regarded the insertion of a foreign body
such as the temporary intrathecal catheter into a poten-
tially infected area as a calculated risk for the introduc-
tion of meningitis. We considered the development of
PRES and SAH as a direct complication of the fre-
quently repeated hypertensive crises.
Based on this case, we propose that ITB infusion
using a temporary intrathecal catheter during emer-
gency situations could be possible in every hospital. In
Figure 2 The approach of the treatment of the infected pump pocket (A, red arrow) as a complication of cellulitis at the orifice of a
suprapubic urine catheter (A, yellow arrow). The implanted port system (B, white arrow) connected with the hardly visible Ascenda
intrathecal catheter percutaneously punctured with a 90° Huber needle (B, green arrow).
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our experience, the higher ITB dose at the end after a
catheter replacement is not uncommon. We are not
aware of a clear explanation. A different intrathecal
catheter tip level or other ventral/lateral/dorsal position
could be an option. Also, it is not excluded that the clini-
cal situation has worsened the spasticity and AD com-
plication, resulting in the need for a higher dose. A
limitation of this study is the retrospective design and
the experience in only one patient.
Conclusion/clinical relevance
The premise of the case is the rapid reintroduction of
ITB (as opposed to IV and oral antispasmodics) in the
setting of ITB withdrawal in particular when associated
with AD to prevent complications (in this case, PRES,
SAH). Further in-depth study is necessary to validate
our observation.
Disclaimer statements
Contributors None.
Conflicts of Interest ED reports fees fromMedtronic Inc.;
FH reports grants and fees from Abbott, Grünenthal; all
outside the submitted work.
References
1 Eldahan KC, Rabchevsky AG. Autonomic dysreflexia after spinal
cord injury: systemic pathophysiology and methods of manage-
ment. Auton Neurosci. Jan 2018;209:59–70.
2 Wan D, Krassioukov AV. Life-threatening outcomes associated
with autonomic dysreflexia: a clinical review. J Spinal Cord Med.
Jan 2014;37(1):2–10.
3 Blackmer J. Rehabilitation medicine: 1. autonomic dysreflexia.
Cmaj Oct. 28 2003;169(9):931–35.
4 Hubli M, Gee CM, Krassioukov AV. Refined assessment of blood
pressure instability after spinal cord injury. Am J Hypertens. Feb
2015;28(2):173–81.
5 Kirshblum SC, House JG, O’Connor KC. Silent autonomic dysre-
flexia during a routine bowel program in persons with traumatic
spinal cord injury: a preliminary study. Arch Phys Med Rehabil.
Dec 2002;83(12):1774–76.
6 Teasell RW, Arnold JM, Krassioukov A, Delaney GA.
Cardiovascular consequences of loss of supraspinal control of the
sympathetic nervous system after spinal cord injury. Arch Phys
Med Rehabil. Apr 2000;81(4):506–16.
7 Kupfer M, Kucer BT, Kupfer H, Formal CS. Persons with chronic
spinal cord injuries in the emergency department: a review of a
unique population. J Emerg Med. 2018;55(2):206–12.
8 Krassioukov A, Tomasone JR, Pak M, et al. The ABCs of AD": A
prospective evaluation of the efficacy of an educational interven-
tion to increase knowledge of autonomic dysreflexia management
among emergency health care professionals. J Spinal Cord Med.
2016;39(2):190–96.
9 Kofler M, Poustka K, Saltuari L. Intrathecal baclofen for auto-
nomic instability due to spinal cord injury. Auton Neurosci-Basic
Clin. Mar 2009;146(1-2):106–10.
10 Vaidyanathan S, Oo T, Soni BM, Hughes PL, Severe SG.
Protracted spasm of urinary bladder and autonomic dysreflexia
caused by changing the suprapubic catheter in a cervical spinal
cord injury patient: treatment by a bolus dose and increased total
daily dose of intrathecal baclofen. Clin Med Insights Case Rep.
2016;9:119–121.
11 Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leu-
koencephalopathy syndrome. N Engl J Med. Feb. 22 1996;334(8):
494–500.
12 SaulinoM, Anderson DJ, Doble J, et al. Best practices for intrathe-
cal baclofen therapy: troubleshooting. Neuromodulation. Aug
2016;19(6):632–41.
13 Popok DW, West CR, Hubli M, Currie KD, Krassioukov AV.
Characterizing the severity of autonomic cardiovascular dysfunc-
tion after spinal cord injury using a novel 24 h ambulatory
blood pressure analysis software. J Neurotrauma. Feb 2017;34
(3):559–66.
14 Elliott S, Krassioukov A. Malignant autonomic dysreflexia in
spinal cord injured men. Spinal Cord. Jun 2006;44(6):386–92.
15 Huang YH, Bih LI, Chen GD, Lin CC, Chen SL, Chen WW.
Autonomic dysreflexia during urodynamic examinations in
patients with suprasacral spinal cord injury. Arch Phys Med
Rehabil. Sep 2011;92(9):1450–54.
Delhaas et al. Intrathecal baclofen as emergency treatment alleviates severe intractable autonomic dysreflexia in cervical spinal cord injury
The Journal of Spinal Cord Medicine 20194
